Application of Tetrameric Recombinant Human Butyrylcholinesterase as a Biopharmaceutical for Amelioration of Symptoms of Acute Organophosphate Poisoning.

Abstract	We present a procedure for optimizing the expression of recombinant tetrameric butyrylcholinesterase that enables large-scale production with the yield >30 mg/liter (>90 mg/roller bottle). Intravenous injection of the preparation significantly increased survival and decreased the severity of symptoms of poisoning with paraoxon, an organophosphorus toxin.
Authors	S S Terekhov, V A Palikov, Y A Palikova, I A Dyachenko, O G Shamborant, I V Smirnov, P Masson, A G Gabibov
Journal	Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 163 Issue 4 Pg. 430-435 (Aug 2017) ISSN: 1573-8221 [Electronic] United States
PMID	28853097 (Publication Type: Journal Article)
Chemical References	Recombinant Proteins Butyrylcholinesterase Paraoxon
Topics	Butyrylcholinesterase (genetics, metabolism) Humans Organophosphate Poisoning (drug therapy) Paraoxon (toxicity) Recombinant Proteins (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!